What’s Fueling End Stage Renal Disease (ESRD) Drug Market Growth? Key Trends and Market Size Forecasts

 The Business Research Company’s report on the End Stage Renal Disease (ESRD) Drug Market provides insights into the global market size, growth rate, regional distribution, competitive landscape, key segments, emerging trends, and strategic opportunities.

 
 How have key drivers contributed to the rapid growth of the end stage renal disease (esrd) drug market?
 Rising cases of obesity and diabetes are expected to propel the growth of the end-stage renal disease (ESRD) drug market going forward. Obesity is described as abnormal or excessive fat buildup that poses a health concern. In contrast, diabetes is a chronic condition that happens when the pancreas does not create enough insulin or when the body cannot utilize the insulin produced efficiently. In patients with renal disease, managing fluid and electrolyte levels, blood pressure, and waste product elimination through dialysis can improve general health and well-being, which may lead to weight reduction and improve blood sugar control. For instance, in March 2022, according to World Obesity, a US-based membership organization representing national and regional associations dedicated to the study and management of obesity, the number of obese people is expected to rise to 892 million in 2025 and then to 1,025 million in 2030. Furthermore, in February 2023, according to the National Health Service, UK-based publicly funded healthcare system, It is estimated that by 2030, the number of people in the UK with diabetes could reach 5.5 million, impacting nearly 9% of the population. Therefore, the rising cases of obesity and diabetes will drive the market for end-stage renal disease (ESRD) drugs.
 
 Access Your Free Sample of the Global End Stage Renal Disease (ESRD) Drug Market Report — Get Insights Now!
 https://www.thebusinessresearchcompany.com/sample.aspx?id=9437&type=smp
 
 How has the end stage renal disease (esrd) drug market size evolved, and what are the latest forecasts for its expansion?
 The end stage renal disease (ESRD) drug market size has grown rapidly in recent years. It will grow from $131.41 billion in 2024 to $149.88 billion in 2025 at a compound annual growth rate (CAGR) of 14.1%. The growth in the historic period can be attributed to increasing incidence of end stage renal disease, growing aging population, improved access to healthcare services, government initiatives and policies, increasing adoption of renal replacement therapies.
 
 The end stage renal disease (ESRD) drug market size is expected to see rapid growth in the next few years. It will grow to $268.44 billion in 2029 at a compound annual growth rate (CAGR) of 15.7%. The growth in the forecast period can be attributed to emerging therapies and drug innovations, increasing healthcare expenditure, rising global burden of chronic kidney diseases, personalized medicine approaches, regulatory support, and expedited approvals. Major trends in the forecast period include increasing incidence of end stage renal disease, advancements in treatment modalities, growing emphasis on precision medicine, development of combination therapies, technological integration in healthcare.
 
 Gain Exclusive Market Insights — Customize Your Research Report Today For Fast Delivery!
 https://www.thebusinessresearchcompany.com/customise?id=9437&type=smp
 
 Which major companies dominate the end stage renal disease (esrd) drug market?
 Major companies operating in the end stage renal disease (ESRD) drug market include Pfizer Inc., AstraZeneca plc, Sanofi SA, Astellas Pharma Inc., Novartis AG, Fresenius SE & Co. KGaA, Takeda Pharmaceutical Company Limited, F. Hoffmann-La Roche Ltd., Kissei Pharmaceutical Co. Ltd., Baxter International Inc., AbbVie Inc., Amgen Inc., Akebia Drugs Inc., Bayer AG, Bristol-Myers Squibb Company, B. Braun SE, Asahi Kasei Medical Co. Ltd., Nikkiso Co. Ltd., Abbott Laboratories, Merck Co. & KGaA
 
 What trends will shape the future of the electronic shelf label market?
 Product innovations are a key trend in gaining popularity in the end-stage renal disease (ESRD) drug market. Major companies operating in the end-stage renal disease (ESRD) drug market are focused on developing innovative solutions to sustain in the market. For instance, in April 2022, GlaxoSmithKline PLC, a UK-based pharmaceutical and biotechnology firm, announced that the US Food and Drug Administration (FDA) accepted the New Drug Application (NDA) for daprodustat, an oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI) for the possible treatment of patients with chronic kidney disease anemia (CKD). The new product is based on the unique Nobel prize-winning science that proved how cells sense and adapt to oxygen availability.
 
 Which region dominates the end stage renal disease (esrd) drug market, and what factors contribute to its leadership?
 North America was the largest region in the end stage renal disease (ESRD) drug market in 2024. The regions covered in the end stage renal disease (ESRD) drug market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
 
 Order Your Report Now For Swift Delivery
 https://www.thebusinessresearchcompany.com/report/end-stage-renal-disease-esrd-drug-global-market-report
 
 How is the end stage renal disease (esrd) drug market segmented, and which segment holds the largest share?
 The end stage renal disease (ESRD) drug market covered in this report is segmented –
 
 1) By Product Type: Calcimimetics, Vitamin D, Sterols, Potassium Binders, Calcium-Based Phosphate Binders, Other Products
 2) By Indication: End Stage Renal Disease (ESRD) Induced Hyperparathyroidism, End Stage Renal Disease (ESRD) Induced Hyperphosphatemia, End Stage Renal Disease (ESRD) Induced Hyperkaliemia
 3) By Distribution Channel: Hospital Pharmacy, Online Pharmacy, Retail Pharmacy
 4) By End User: Hospitals, Homecare, Specialty Clinics, Other End Users
 
 Subsegments:
 1) By Calcimimetics: Cinacalcet, Etelcalcetide
 2) By Vitamin D: Calcitriol, Doxercalciferol, Paricalcitol
 3) By Sterols: Ergocalciferol, Cholecalciferol
 4) By Potassium Binders: Sodium Polystyrene Sulfonate, Patiromer, Sodium Zirconium Cyclosilicate
 5) By Calcium-Based Phosphate Binders: Calcium Acetate, Calcium Carbonate
 6) By Other Products: Iron Supplements, Erythropoiesis-Stimulating Agents
 
 Purchase The Exclusive Report Now To Unlock Valuable Market Insights:
 https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=9437
 
 How is the end stage renal disease (esrd) drug market defined, and what are its core characteristics?
 End stage renal disease (ESRD) drug is a drug used to treat a medical illness in which a person’s kidneys stop working permanently, requiring a kidney transplant or a regular regimen of long-term dialysis to protect life. It is crucial in treating and preventing secondary problems in individuals with chronic renal disease (CKD).
 
 About The Business Research Company:
 
 With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead. 
 
 Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making. 
 
 Contact Us:
 
 The Business Research Company 
 
 https://thebusinessresearchcompany.com/
 
 Europe: +44 207 1930 708 
 
 Asia: +91 88972 63534 
 
 Americas: +1 315 623 0293 
 
 Email: info@tbrc.info 
 
 
 Follow Us On:
 
 LinkedIn: https://in.linkedin.com/company/the-business-research-company